Contraction of 42% in the third quarter. Pharma giant talks about 'exceptional effects'
Novartis faces sharp fall in profit. For the third quarter of the year, it stood at 1.8 billion francs, an annual decrease of 42%.
According to the pharmaceutical industry giant, this decline can be explained by "exceptional elements": the company cites in this sense an extraordinary gain obtained in 2014 thanks to a sale of shares, as well as the creation of a commission intended for the costs of legal disputes.
However, a decrease was also recorded in terms of turnover: the company's turnover fell by 6% and currently reaches a total of 12.3 billion dollars.
Related news: Novartis discounts the US sanctions but the quarterly is still below the consensus
